Prescription Cannabis Abroad: The Legal Grey Zones That Can Strand You at the Border

A valid prescription does not protect you at every border. Here is what prescription cannabis travellers need to know before they fly.

Prescription cannabis abroad: what you need to know

Carrying a valid prescription for cannabis-based medication does not guarantee entry into another country. Customs officers do not weigh your doctor's letter against their national narcotics law. They apply the law. In some countries, that law treats your medication as a criminal offence regardless of why you take it.

The legal landscape spans almost the full range of national drug-policy regimes. At one end, Germany legalised recreational cannabis on 1 April 2024 and removed medical cannabis from the controlled-substances schedule on the same date. At the other, Singapore retains the death penalty for cannabis trafficking above 500 grams under the Misuse of Drugs Act, with no medical exemption for foreign visitors. Most countries sit somewhere in between: controlled but accessible domestically, restricted at the border for travellers carrying a foreign prescription.

Form matters as much as country. A vial of liquid CBD isolate with less than 0.2% THC is treated as an over-the-counter wellness product in much of Europe and as a prescription medicine in others. A 5-gram tin of cannabis flower at 22% THC is treated as a controlled narcotic almost everywhere. An FDA-approved oral solution of pure cannabidiol (Epidiolex, prescribed for treatment-resistant childhood epilepsy) is treated as a routine pharmaceutical in dozens of countries that prohibit plant cannabis outright. Knowing which legal category your specific product falls into is more useful than knowing the destination's general cannabis policy.

Medical disclaimer: This article provides general information for travellers and does not constitute medical advice. Regulations, prescription requirements, and product availability change. Consult your prescribing clinician before travelling and confirm destination-specific rules with the relevant national authority.

Why a prescription is not a passport

The core problem is a mismatch between national law and medical reality. Cannabis sat in Schedule IV, the 1961 UN Single Convention's most restrictive tier reserved for drugs deemed to have no medical use, from 1961 until December 2020, when the UN Commission on Narcotic Drugs voted 27-25-1 to move it down to Schedule I^[1] on a WHO Expert Committee recommendation. Schedule I is still tightly controlled, and most countries still treat plant cannabis as a controlled substance domestically. National implementation runs the full spectrum from full legalisation (Germany, Canada, Uruguay, several US states) to capital-punishment trafficking laws (Singapore, Malaysia).

The result is that two countries can both permit medical cannabis for residents, yet each classifies the other's patients as smugglers at the border. This is not a theoretical edge case. It has resulted in arrests, medication confiscation, and deportation.

Countries where import is permitted with documentation

A small number of countries formally permit travellers to import cannabis-based medicines under strict conditions. The Netherlands allows registered patients to carry a Schengen Certificate for controlled medicines^[2], which is issued by the prescribing country's health authority and accepted at borders across the Schengen Area for up to 30 days.

Germany, which legalised cannabis for recreational use in April 2024, still requires a prescription and patient documentation for medicinal cannabis import. The German Federal Institute for Drugs and Medical Devices (BfArM) permits medicinal cannabis for personal use within the Schengen zone^[3], provided the Schengen Certificate accompanies the patient. Without the certificate, the medication is treated as an illegal narcotic at border entry.

Canada permits residents to leave with personal-use cannabis, but this protection evaporates the moment you cross any international border. Canadian law cannot override another country's customs authority.

Country case studies: where the medical-cannabis system actually works for travellers

Germany. Since 1 April 2024 medical cannabis has been regulated under the Medizinal-Cannabisgesetz (MedCanG) rather than the Betäubungsmittelgesetz (BtMG). Doctors no longer need to issue a Betäubungsmittel-Rezept (BtM-Rezept) for cannabis flower or extracts; a normal e-prescription is sufficient. Only the synthetic THC analogue nabilone remains on the BtMG. For incoming travellers, Germany accepts a Schengen Certificate from EU/EEA prescribers; for stays beyond 30 days, registering with a German GP and obtaining a local prescription is straightforward in most major cities, with private cannabis-focused clinics in Berlin, Munich, Frankfurt, Hamburg, and Cologne offering same-week or next-week appointments.

Israel. The Ministry of Health's Medicinal Cannabis Unit (Yakar) administers patient licenses; approximately 137,000 Israeli residents held active medical-cannabis licenses as of March 2024, one of the highest per-capita rates worldwide. Foreign cannabis prescriptions and licenses are not recognised. Visitors needing continuation cannot transfer their home authorisation; they must either bring their own supply (and tolerate the customs risk), apply for a temporary Yakar license through an Israeli physician (rarely granted for short-stay tourists), or transition off cannabis for the duration of the trip.

Australia. The TGA operates two patient-access pathways for unapproved medicinal cannabis: the Special Access Scheme Category B (SAS-B), an application-per-patient approval, and the Authorised Prescriber (AP) scheme, which permits a registered specialist to treat a class of patients without per-patient approval. Cannabis products are stratified across five TGA categories by cannabinoid content (Category 5 = Schedule 8 high-THC). For incoming travellers, Australia's Traveller's Exemption permits up to a three-month personal supply with a doctor's letter on letterhead, but Schedule 8 products remain subject to the Office of Drug Control rules. Local prescribing through a private cannabis clinic is the most reliable continuation path for longer stays.

United Kingdom. Medical cannabis was rescheduled to Schedule 2 in November 2018 but remains effectively private-only, and NHS prescribing is rare. Access is through specialist private clinics (Sapphire Medical, Mamedica, Curaleaf, Leva, Releaf, others) with initial consultations typically £150–£250 and monthly medication costs £150–£400. Project Twenty21, Europe's first large medical-cannabis patient registry, concluded data collection at the end of 2024; Sapphire Access Scheme and CPASS (Cannabis Patient Advocacy & Support Services) continue. Foreign cannabis prescriptions are not recognised at UK pharmacies, but the Home Office does permit travellers to carry up to a 30-day supply of their lawfully-prescribed medicine on entry with supporting documentation.

Other established markets. Canada (federal medical-cannabis system since 2001), the Netherlands (the original Bedrocan programme since 2003), Israel, Czechia, Italy, Portugal, Greece, Croatia, and Spain (regulated patient access via state pharmacies) all have functioning medical-cannabis frameworks. Emerging programmes in Mexico (Cofepris regulations, slow implementation), Argentina (Reprocann registry since 2020), Colombia, Thailand (re-restricted to medical-only June 2025), and Malta all involve country-specific prescribing rules that do not honour foreign authorisations.

Countries where import carries serious legal risk

Singapore, Indonesia, and the United Arab Emirates treat all cannabis as a Class A or equivalent narcotic with no medical exemption for foreign visitors. Singapore's Misuse of Drugs Act carries up to 10 years imprisonment or a S$20,000 fine for possession, and the death penalty for trafficking more than 500 grams^[4]; tourists are subject to the same penalties as residents. Japan amended its Cannabis Control Law on 12 December 2024 to open a narrow pharmaceutical pathway for low-THC, CBD-based pharmaceutical products such as Epidiolex (for treatment-resistant epilepsy), but plant cannabis, THC concentrates, and tourist personal supplies remain criminal with no foreign-prescription exemption. Possession in Japan carries up to five years imprisonment for tourists and residents alike.

Thailand presents a particular trap. The country removed cannabis from its narcotics list in 2022, which triggered a brief commercial boom, with recreational shops, infused menus, and tourist marketing built up around the policy. On 26 June 2025 the Thai government reversed course via a notification published in the Royal Gazette, effective immediately: cannabis sale, possession, and consumption are now strictly limited to certified medical purposes and require a prescription from a licensed Thai practitioner, valid for no more than 30 days. Foreign prescriptions are not recognised.

Travellers who relied on 2022-2024 reporting arrived in 2025 to find a completely different legal regime: the same shops, the same product, prosecutable as a controlled substance. This illustrates the central risk: cannabis law changes faster than travel advice will be updated, often in the direction of greater restriction, sometimes overnight. Before flying with any cannabis-based medicine, verify the destination's current legal status with the national health regulator (not a general travel forum) within two weeks of departure.

Drug form: flower, oil, edibles and CBD, and why the same prescription splits at customs

Customs officers do not see your medication as a single regulatory item. They see a specific product form with a measurable cannabinoid profile, and most national laws treat each form differently.

THC-dominant flower (≥0.3% THC). The strictest form everywhere. Even in countries with active medical-cannabis programmes (Germany, Australia, the Netherlands), flower is more visible at customs, more obviously identifiable, and often triggers a higher level of scrutiny than oils or capsules. If you can substitute to an oil or capsule formulation before travelling, it removes the simplest sniff-and-search detection method.

Cannabis oils and extracts. Generally treated under the same controlled-narcotic framework as flower, but customs detection is less obvious. THC concentration matters: some countries (Japan, Singapore, the Gulf states) treat any detectable THC as a narcotic regardless of concentration. Others (Switzerland, parts of the EU, Brazil) draw a 0.2-0.3% THC line above which the product becomes prescription-only or prohibited.

CBD-only products (THC <0.2-0.3%). Legality varies sharply: OTC wellness product in much of Europe, the UK, the US, and Latin America; prescription-only in Australia and parts of Asia; prohibited entirely in Japan above 1 ppm THC, Singapore, the UAE, and Saudi Arabia. Always carry the certificate of analysis (CoA) showing THC concentration for the specific batch, because a third-party CoA matters more at customs than the label.

Edibles, vapes, and infused products. The riskiest form in most jurisdictions. Even where flower or oils are permitted, edibles and vape cartridges face additional restrictions because of dosing inconsistency, packaging that resembles regular food/drink, and elevated overdose-risk profiles in pediatric exposures. Many countries (including Germany under MedCanG) restrict the forms a pharmacy can dispense; tourist-purchase products may not be legal to take across the border at all.

Cannabinoid pharmaceuticals: Epidiolex, Sativex, and Nabilone travel as ordinary medicines

Three cannabinoid-based products are regulated as fully-approved pharmaceuticals in most major markets, which means they travel under the normal prescription-medication rules of the destination country rather than under cannabis import rules. This is the cleanest path for patients whose underlying indication can be treated with one of them.

Epidiolex / Epidyolex (cannabidiol oral solution). FDA-approved (2018) and EMA-approved (2019) for treatment-resistant epilepsy in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. Also approved in the UK (MHRA), Australia (TGA), Switzerland (Swissmedic), Israel (Ministry of Health), and New Zealand. As of 2024, not yet PMDA-approved in Japan (a 2024 Phase 3 trial missed its primary efficacy endpoint). Where approved, Epidiolex travels as a normal Schedule V or unscheduled prescription medicine, not under cannabis import rules, which is a major advantage for pediatric epilepsy families travelling internationally.

Sativex / nabiximols (THC + CBD oromucosal spray). Approved in approximately 29 countries, including the UK (the first regulatory approval, in June 2010), Canada, Germany, France, Spain, Italy, the Netherlands, Denmark, Sweden, the Czech Republic, and Australia, for moderate-to-severe spasticity in multiple sclerosis. Not FDA-approved in the United States. Now marketed by CNX Therapeutics. Sativex is the clearest example of a cannabis-derived medicine that is regulated identically to other prescription drugs in its approved markets, with no special customs treatment.

Nabilone (synthetic THC analogue). Approved in the US (Cesamet, Schedule II), the UK (Cesamet, Schedule II of the Misuse of Drugs Regulations), Canada, Mexico, Germany (the one cannabis-related product Germany kept on the BtMG after its April 2024 reforms), and several other markets for chemotherapy-induced nausea and vomiting. As a synthetic single-molecule pharmaceutical, nabilone avoids most of the cross-border friction associated with plant cannabis, though its Schedule II / BtM status still requires the standard controlled-substance paperwork at customs.

The Schengen zone: one certificate, 27 countries, one catch

The Schengen Certificate for controlled medicines is the closest thing to a standardised cross-border permission document that exists for patients. The certificate must be issued by the competent national authority of the country where the medication was prescribed^[5], and it is valid for a maximum of 30 days within the Schengen Area.

The catch is that the certificate covers Schengen zone transit, not final destinations outside Schengen. Flying from Amsterdam to Bangkok with a Schengen Certificate does not provide any protection at Thai customs.

A second catch: you must apply for the certificate before you travel. Processing times vary by country and can take two to four weeks. Leaving this to the week before departure is a common and costly mistake.

What to prepare before you fly

Start with medication import rules for every country on your itinerary, not just your final destination. A connecting flight through a country with a zero-tolerance policy can cause as much trouble as landing there.

Contact the embassy of every destination and transit country at least six weeks before departure. Ask specifically whether medicinal cannabis import is permitted under any circumstance. Get the answer in writing.

Apply for the Schengen Certificate from your prescribing country's competent authority if you are travelling within the Schengen Area. In many countries this is the health ministry or a designated medicines regulatory agency.

Carry the medication in its original labelled packaging. A relabelled container or a pill organiser is a customs red flag. The product name on the label should match the product name on your prescription.

Have a notarised translation of your prescription for any country where English is not widely used in official settings. A Spanish, Japanese, or Arabic translation of your diagnosis and prescription reduces the risk of a lengthy customs interrogation.

Know the quantity limit. Even countries that permit medicinal cannabis import typically cap the amount at a personal supply, most commonly 30 days. Carrying more than the permitted quantity can trigger a controlled substance trafficking charge.

When your medication is confiscated at the border

Confiscation does not automatically mean prosecution. In most EU countries, first-time travellers with small quantities and clear documentation are more likely to have the medication confiscated than to face criminal charges. The outcome depends heavily on the officer's discretion and the national enforcement policy at that time.^[6]

If your medication is seized, do not argue and do not attempt to reclaim it by force. Ask for a written receipt listing what was taken. Contact your country's embassy or consulate immediately. Consular staff can provide a list of local legal representatives.

In countries such as Japan, Singapore, or the UAE, the situation is materially different. Confiscation typically initiates a criminal process. Legal representation should be secured before making any statement to authorities.

The alternative: sourcing locally

Some travellers assume they can fill a local prescription at their destination. This works in a small number of countries with mature systems: Germany (via a Betäubungsmittel-prescription from a GP or specialist), the Netherlands (via a hospital pharmacy with consultant authorisation), Australia (via the TGA's Special Access Scheme or Authorised Prescriber pathway), Canada (via the Cannabis Act medical authorisation), and Israel (via an Israeli Ministry of Health Yakar licence). In every case, the local prescription pathway requires being seen by a domestic clinician with prescribing authority, and foreign cannabis prescriptions are not recognised; even Israel's mature medical-cannabis system, with around 120,000 active patients, does not transfer foreign licences.

Local sourcing is rarely a practical emergency solution. Initiate any application processes at least three to four weeks before departure. For most destinations, carry your full supply.

Keep your documentation complete and accessible

Your medication list, diagnoses, and prescribing physician's details are the documents most likely to prevent a minor border problem from becoming a major legal one. Storing them in a structured, portable format matters.

Nomedic generates an International Patient Summary that consolidates your medication list, diagnoses, and prescriber information into a single standardised record. Your medical record in IPS format is readable by border health officials, customs officers, and emergency departments in any country that uses the standard.

A printed copy in your carry-on and a digital copy accessible offline are the minimum. Keep one copy in your checked luggage as a backup in case your carry-on is delayed.

This article provides general information about cannabis-based medication and international travel. It does not constitute legal advice. Cannabis laws change frequently and vary significantly between and within countries. Consult a qualified legal professional and your prescribing physician before travelling with controlled medications. Verify all information with the relevant embassy or consulate before departure.

Frequently asked questions

Can I travel within the Schengen Area with prescription cannabis?

Yes, if you hold a Schengen Certificate for controlled medicines issued by the competent authority in your prescribing country. The certificate is valid for up to 30 days and must be applied for before travel. Without it, your medication may be confiscated at any Schengen border.

Does a valid prescription protect me from arrest at customs?

Not in countries that classify cannabis as a narcotic without a medical exemption for foreign nationals. In Japan, Singapore, Indonesia, and the UAE, a prescription does not constitute a legal defence. Carry only what is legally permitted in each destination and transit country.

What happens if my cannabis medication is confiscated at a border?

Request a written receipt for the confiscated items and contact your country's embassy or consulate immediately. In most EU countries this is an administrative matter. In countries with zero-tolerance narcotics laws, it may initiate criminal proceedings and you should secure legal representation before making any statement.

Can I get a local prescription for cannabis at my travel destination?

A small number of countries, including Australia and Israel, have processes that may allow foreign patients to access medicinal cannabis locally. These processes take days to weeks and require a registered local prescriber. They are not a viable emergency solution.

Is prescription cannabis legal to carry on a flight?

IATA regulations govern what airlines permit on board, but each country's customs law governs what you can legally import. Even if an airline permits medicinal cannabis in checked luggage, you may commit an offence when you land. The critical point is the destination country's law, not the airline's policy.

How do I carry documentation for my cannabis prescription at a border?

Carry the original labelled packaging, your prescription, a doctor's letter on headed paper, and any applicable permits such as the Schengen Certificate. A notarised translation in the local language of your destination reduces the risk of a prolonged customs stop.